Articles related to FDA

Explore groundbreaking therapies in the pipeline: Onivyde for pancreatic cancer, showing marked survival benefits, and roluperidone, offering new hope in managing schizophrenia’s negative symptoms.

In a major stride for cervical cancer treatment, the FDA-approved pembrolizumab in combination with CRT demonstrates significant improvement in progression-free survival for FIGO 2014 stage III-IVA patients, marking a pivotal change in therapeutic approaches.

CARsgen Therapeutics faces a critical juncture as the FDA places a clinical hold on three of its key CAR-T cell therapy candidates, highlighting the paramount importance of manufacturing standards in the realm of advanced oncology treatments.

Belzutifan’s FDA approval, following the LITESPARK-005 trial results, represents a significant stride in treating advanced kidney cancer, offering a novel therapeutic option for patients who have exhausted standard treatments.

An in-depth look at the FDA’s clinical hold on Iovance’s lung cancer cell therapy trial reveals crucial insights into the safety and progression of innovative cancer treatments.

A look into the FDA’s rigorous 2023 drug approval process, including a record number of new medicines and notable rejections. Understanding these trends is essential for anticipating future treatment landscapes.